Argatroban Dosing in Intensive Care Patients with Acute Renal Failure and Liver Dysfunction

Pharmacotherapy

Volumn 24, Issue 3, 2004, Pages 409-414

  Williamson, David R ^a,b   Boulanger, Isabelle ^a,b   Tardif, Mariline ^a,b   Albert, Martin ^a   Grégoire, Geneviève ^a,b  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Argatroban; Complications; Hepatic dysfunction; HIT; Intensive care unit

Indexed keywords

AMINOTRANSFERASE; ARGATROBAN; HEPARIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CASE REPORT; DOSE CALCULATION; DRUG ELIMINATION; FEMALE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; INTERNATIONAL STANDARD UNIT; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; LIVER LEVEL; MALE; PARTIAL THROMBOPLASTIN TIME; THROMBOCYTOPENIA;

AGED; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN; HUMANS; INFUSIONS, PARENTERAL; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE, ACUTE; LIVER DISEASES; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; RENAL REPLACEMENT THERAPY; THROMBOCYTOPENIA; TRANSAMINASES;

EID: 1542346478     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.4.409.33168     Document Type: Article

References (20)

1. Warkentin TE, Barkin RL. Newer strategies for the treatment of heparin-induced thrombocytopenia. Pharmacotherapy 1999;19:181-95.
2. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-55.
3. Wilde MI, Markham A. Danaparoid: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997;54:903-24.
4. Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2002;36:489-503.
5. Lubenow N, Greinacher A. Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin. J Thromb Thrombolysis 2000;10:547-57.
6. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
7. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-93.
8. Kern H, Ziemer S, Kox WJ. Bleeding after intermittent or continuous r-hirudin during CRRT. Intensive Care Med 1999;25:1311-14.
9. Westphal K, Martens S, Strouhal U, Matheis G, Lindhoff-Last E, Wimmer-Greinecker G. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure. Thorac Cardiovasc Surg 1997;45:318-20.
10. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29.
11. Texas Biotechnology Corporation. Argatroban package insert. Houston, TX; 2002.
12. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997;23:503-16.
13. McKeage K, Plosker GL. Argatroban. Drugs 2001;61:515-22.
14. Ahmad S, Ahsan A, George M, et al. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. Clin Appl Thromb Hemost 1999;5:252-8.
15. Tran JQ, DiCicco RA, Sheth SB, et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999;39:513-19.
16. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs: a review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 2002;57:751-8.
17. Keng TB, Chong BH. Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-hirudin. Br J Haematol 2001;114:394-6.
18. Koster A, Meyer O, Hausmann H, Kuppe H, Hetzer R, Mertzlufft F. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery. J Clin Anesth 2000;12:324-7.
19. Willey ML, de Denus S, Spinler SA. Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis. Pharmacotherapy 2002;22:492-9.
20. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002;105:401-5.